Extension study data for Gilenya® shows patients successfully treated for up to 7 years
New data will be presented at the 64th annual meeting of the American Academy of Neurology (AAN) that support the efficacy and safety profile of Gilenya® (fingolimod), the only oral therapy approved to treat relapsing forms of multiple sclerosis (MS).
"The data being presented reinforce our confidence in the sustained efficacy and safety profile of Gilenya," said David Epstein, Head of the Pharmaceuticals Division of Novartis Pharma AG.
New data presented on long-term efficacy and safety profile of Gilenya.
New results from the phase III FREEDOMS extension study showed significant improvements in clinical and MRI measures in patients who switched from placebo (administered during the 24-month core study) to Gilenya (administered during the extension).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309